Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.

J Biol Response Mod. 1985 Dec;4(6):596-601. Unique Identifier : AIDSLINE MED/86114126
Siegel JP; Lane HC; Stocks NI; Quinnan GV Jr; Fauci AS

Abstract: Intravenous infusions of 250,000 U of lymphocyte-derived or recombinant DNA-derived interleukin-2 (IL-2) were administered to patients with the acquired immunodeficiency syndrome, and sera were obtained for pharmacokinetic studies. A methodology was developed for the determination of serum levels of interleukin-2, which resulted in a coefficient of variation of less than 8% and a sensitivity 32-fold greater than that of the traditional methodology using probit analysis of half-maximal stimulation. In addition to the previously described rapid clearance of IL-2, a later phase of interleukin-2 clearance with a half-life greater than 90 min was observed; bioactive interleukin-2 remained in the circulation for several hours after infusion.
Keywords: Acquired Immunodeficiency Syndrome/*BLOOD/THERAPY Clinical Trials DNA, Recombinant Half-Life Human Infusions, Parenteral Interleukin-2/ADMINISTRATION & DOSAGE/ISOLATION & PURIF/ *PHYSIOLOGY Kinetics Lymphocytes/IMMUNOLOGY CLINICAL TRIAL JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDblood/therapyclinicaltrialsdna,recombinanthalf-lifehumaninfusions,parenteralinterleukin-2/administration&dosage/isolation&purif/KWDphysiologykineticslymphocytes/immunologyclinicaltrialjournalarticle
860530
M8650180

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .